Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S366000, C514S371000, C514S364000, C548S150000, C548S151000, C548S195000, C548S196000, C548S131000
Reexamination Certificate
active
07875639
ABSTRACT:
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof,wherein R1, R2, R3, R4, and L2, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
REFERENCES:
patent: 2004/0077617 (2004-04-01), Bennani et al.
patent: 2008/0064699 (2008-03-01), Florjancic et al.
patent: 2008/0312435 (2008-12-01), Saito et al.
patent: 01/16138 (2001-08-01), None
patent: 2003049741 (2003-06-01), None
patent: 2006051704 (2006-05-01), None
patent: WO 2006051704 (2006-05-01), None
Rautio et al. Nature Reviews Drug Discovery 2008, 7, pp. 255-270.
Wang et al. Drug Delivery: Principles and Applications, 2005 John Wiley & Sons, Inc. Publication, Section 8.3, pp. 136-137.
Smith, D. A. Current Opinion in Drug Discovery & Development 2007, 10, 550-559.
Testa, B. Current Opinion in Chemical Biology 2009, 13, pp. 338-344.
Alfaro, I., et al., “Dihydroaromatic compounds in the Diels-Alder reaction—III : In situ generation and Diels-Alder reaction of cyclohexa-1,3-dienes”, Tetrahedron, vol. 26, pp. 201-218, 1970.
Arevalo-Martin, A., et al., “Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis”, Journal of Neuroscience, vol. 23, No. 7, pp. 2511-2516, 2003.
Baker, T.J., et al., “Regiospecific Vinyl Phosphate/β-Keto Phosphonate Rearrangements Initiated by Halogen-Metal Exchange”, Journal of Organic Chemistry, vol. 63, No. 8, pp. 2613-2618, 1998.
Benito, C., et al., “Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains”, Journal of Neuroscience, vol. 23, No. 35, pp. 11136-11141, 2003.
Benito, C., et al., “A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis”, Journal of Neuroscience, vol. 25, No. 10, pp. 2530-2536, 2005.
Bouchard, J.-F., et al., “Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart”, Life Sciences, vol. 72, pp. 1859-1870, 2003.
Boyle, W. J., et al., “Osteoclast differentiation and activation”, Nature, vol. 423, pp. 337-342, 2003.
Brennan, T.J., et al., “Characterization of a rat model of incisional pain”, Pain, vol. 64, p. 493, 1996.
Buckley, N.E., et al., “Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB receptor”, European Journal of Pharmacology, vol. 396, pp. 141-149, 2000.
Carlisle, S. J., et al., “Differential expression of the CB cannabinoid receptor by 2 rodent macrophages and macrophage-like cells in relation to cell activation”, International Immunopharmacology, vol. 2, p. 69, 2002.
Carrier, E. J., et al., “Endocannabinoids in Neuroimmunology and Stress”, Current Drug Targets—CNS & Neurological Disorders, vol. 4, pp. 657-665, 2005.
Casanova, M. L., et al., “Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannibinoid receptors”, Journal of Clinical Investigation, vol. 111, pp. 43-50, 2003.
Chaplan, S.R., et al., “Quantitative assessment of tactile allodynia in the rat paw”, Journal of Neuroscience Methods, vol. 53, p. 55-63, 1994.
Cichewicz, D. L., et al., “Synergistic interactions between cannabinoid and opioid analgesics”, Life Sciences, vol. 74, pp. 1317-1324, 2004.
Clayton, N., et al., “CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain”, Pain, vol. 96, pp. 253-260, 2002.
Dauben, W. G., et al., “Organic reactions at high pressure. Cycloadditions with furans”, Journal of the American Chemical Society, vol. 98, No. 7, pp. 1992-1993, 1976.
Dixon, W.J., “Efficient analysis of experimental observations”, Annual Review of Pharmacology and Toxicology, vol. 20, p. 441-462, 1980.
Filippo, C. D., et al., “Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN”, Journal of Leukocyte Biology, vol. 75, pp. 453-459, 2004.
Galiègue, et al., “Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations”, European Journal of Biochemistry, vol. 232, pp. 54-61, 1995.
Golech, S. A., et al., “Human brain endothelium: coexpression and function of vannilloid and endocannabinoid receptors”, Molecular Brain Research, vol. 132, pp. 87-92, 2004.
Grotenhermen, F., et al., “IACM 2ndConference on Cannabinoids in Medicine”, Expert Opinion in Pharmacotherapy, vol. 4, No. 12, pp. 2367-2371, 2003.
Hargreaves, et al., “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia”, Pain, vol. 32, p. 77, 1988.
Hanu{hacek over (s)}, L., et al., “HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor”, Proceedings of the National Academy of Science, vol. 96, pp. 14228-14233, 1999.
Hohmann, A. G., et al., “Selective Activation of Cannabinoid CB2 Receptors Suppresses Hyperalgesia Evoked by Intradermal Capsaicin”, Journal of Pharmacology and Experimental Therapeutics, vol. 308, pp. 446-453, 2004.
Ibrahim, M. M., et al., “Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present I the CNS”, Proceedings of the National Academy of Science, vol. 100, No. 18, pp. 10529-10533, 2003.
Ibrahim, M. M., et al., “CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids”, Proceedings of the National Academy of Science, vol. 102, No. 8, pp. 3093-3098, 2005.
Idris, A.I., et al., “Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors”, Nature Medicine, vol. 11, pp. 774-779, 2005.
Ihenetu, K., et al., “Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids”, European Journal of Pharmacology, vol. 458, pp. 207-215, 2003.
Jasys, V. J., et al., “Preparation of Fluoroadamantane Acids and Amines: Impact of Bridgehead Fluorine Substitution on the Solution- and Solid-State Properties of Functionalized Adamantanes”, Journal of the American Chemical Society, vol. 122, pp. 466-473, 2000.
Julien, B., et al., “Antifibrogenic Role of the Cannabinoid Receptor CB2 in the Liver”, Gastroenterology, vol. 128, pp. 742-755, 2005.
Karsak, M., et al., “Cannabinoid receptor type 2 gene is associated with human osteoporosis”, Human Molecular Genetics, vol. 14, No. 22, pp. 3389-3396, 2005.
Kim, S.H., et al., An experimental model for peripheral neuropathy produced by segmental spinal nerve litigation in the rat, vol. 50, p. 355-363, 1992.
Kreutzberg, G. W., “Microglia: a sensor for pathological events in the CNS”, Trends in Neuroscience, vol. 19, pp. 312-318, 1996.
Lepicier, P., et al., “Endocannabinoids protect the rat isolated heart against ischaemia”, British Journal of Pharmacology, vol. 139, pp. 805-815, 2003.
Lotersztajn, S., et al., “Hepatic Fibrosis: Molecular Mechanisms and Drug Targets”, Annual Review of Pharmacology and Toxicology, vol. 45, pp. 605-628, 2005.
Malan, T. P., et al., “CB2 cannabinoid receptor-mediated peripheral antinociception”, Pain, vol. 93, pp. 239-245, 2001.
Maresz, K., et al., “Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli”, Journal of Neurochemistry, vol. 95, pp. 437-445, 2005.
Masciadri, R., et al., “Regioselective Friedel—Crafts Alkylation of Anilines and Amino-Substituted Heteroarenes with Hexafluoroacetone Sesquihydrat
Carroll William A.
Dart Michael J.
Florjancic Alan S.
Frost Jennifer M.
Gallagher Megan E.
Abbott Laboratories
Anderson Rebecca L
Coughlin Matthew P
Parial Andrew M.
LandOfFree
Compounds as cannabinoid receptor ligands and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as cannabinoid receptor ligands and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as cannabinoid receptor ligands and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712078